摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester | 724477-07-0

中文名称
——
中文别名
——
英文名称
1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester
英文别名
1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-4-carboxylic acid ethyl ester;ethyl 1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-6-oxo-5H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-4-carboxylate
1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester化学式
CAS
724477-07-0
化学式
C24H29BrN4O3
mdl
——
分子量
501.423
InChiKey
BXPHWFARPZDBHK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    75.6
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE A SUBSTITUTION PAR UN GROUPE AMINO CYCLIQUE
    申请人:TAISHO PHARMA CO LTD
    公开号:WO2004058767A1
    公开(公告)日:2004-07-15
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.[SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    本发明的一个目的是提供一种针对CRF受体的拮抗剂,该拮抗剂可作为治疗或预防剂用于CRF被认为参与的疾病,如抑郁症、焦虑症、阿尔茨海默病、帕森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症等疾病。[解决方案] 一种用下式[I]表示的含有环状基团的吡咯嘧啶吡咯吡啶衍生物具有高亲和力对CRF受体,并对CRF被认为参与的疾病有效。
  • Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
    申请人:Nakazato Atsuro
    公开号:US20050209253A1
    公开(公告)日:2005-09-22
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. [Solution] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    本发明的目的是提供一种针对CRF受体的拮抗剂,作为治疗或预防CRF参与的疾病的有效药物,例如抑郁症、焦虑症、阿尔茨海默病、帕森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合症、睡眠障碍、皮肤炎、精神分裂症等。[解决方案] 一种以以下公式[I]表示的带有环状基基团的吡咯嘧啶吡咯吡啶衍生物,具有与CRF受体的高亲和力,并对CRF参与的疾病有效。
  • Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group
    申请人:NAKAZATO Atsuro
    公开号:US20080287397A1
    公开(公告)日:2008-11-20
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    本发明的目的是提供一种CRF受体拮抗剂,作为治疗或预防与CRF有关的疾病的药物,例如抑郁症、焦虑症、阿尔茨海默病、帕森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等。这个问题可以通过下式[I]所表示的带有环状基基团的吡咯嘧啶吡咯吡啶衍生物来解决,其具有高亲和力,对CRF受体有效,并且对与CRF有关的疾病也有效。
  • PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP
    申请人:NAKAZATO Atsuro
    公开号:US20110130364A1
    公开(公告)日:2011-06-02
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    本发明的目的是提供一种CRF受体拮抗剂,该拮抗剂作为治疗或预防CRF参与的疾病的药物,如抑郁症、焦虑症、阿尔茨海默病、帕森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等方面有效。这个问题可以通过一种代表式[I]下的带有环状基基团的吡咯咪啉或吡咯吡啶衍生物来解决,该衍生物对CRF受体具有高亲和力,并对CRF参与的疾病有效。
  • Pyrrolopyridine derivatives substituted with cyclic amino group
    申请人:Nakazato Atsuro
    公开号:US08455511B2
    公开(公告)日:2013-06-04
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    本发明的目的是提供一种CRF受体拮抗剂,作为治疗或预防CRF参与的疾病的有效药物,如抑郁症、焦虑症、阿尔茨海默病、帕森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症等。可以通过使用下式[I]所表示的带有环状基基团的吡咯嘧啶吡咯吡啶衍生物来解决这个问题,该衍生物对CRF受体具有高亲和力,并对CRF参与的疾病有效。
查看更多

同类化合物

(2R,3S,5R)-5-(4-氨基-7H-吡咯[2,3-D]嘧啶-7-基-2 -(羟甲基)四氢呋喃-3-醇 鲁索替尼 鲁索利尼杂质C 酸蓝129:1 迪高替尼 诺那吡胺 螺[4.4]壬烷-1-酮,6-氨基-,(5S,6S)- 苯酚,2,4-二氯-5-肼-,单盐酸 苯并呋喃,2,3-二氢-3-(1-甲基乙基)- 芦可替尼杂质5 芦可替尼杂质3 芦可替尼杂质2 聚(氧代-1,2-乙二基),a-甲基-w-[[3,4,4,4-四氟-2-[1,2,2,2-四氟-1-(三氟甲基)乙基]-1,3-二(三氟甲基)-1-丁烯-1-基]氧代]- 维贝格龙 磷酸鲁索替尼 甲基7-(2-甲氧基乙基)-1,3-二甲基-2,4-二羰基-2,3,4,7-四氢-1H-吡咯并[2,3-D]嘧啶-6-羧酸酯 甲基6,7-二氢-5H-吡咯并[3,4-D]嘧啶-2-甲酸基酯 氰基酰胺,(1-甲基-2-吡咯烷亚基)-(9CI) 杂质TFTB 替诺福韦杂质113 托法替布杂质ZJT2-I 托法替尼杂质28 托法替尼杂质2 托伐替尼杂质T 异丙基2-氨基-4-甲氧基-7h-吡咯并[2,3-d]嘧啶-6-羧酸 巴里替尼杂质5 巴瑞替尼杂质9 巴瑞替尼 巴瑞克替尼杂质 巴瑞克替尼中间体3 巴瑞克替尼中间体1 外消旋鲁替替尼-d8 培美酸 培美曲塞杂质 吡啶,1-[(2,5-二甲基苯基)甲基]-1,2,3,6-四氢- 吡咯并[1,2-a]嘧啶-3-羧酸 吡咯并[1,2-F]嘧啶-3-甲酸乙酯 吡咯并[1,2-C]嘧啶-4-腈 吡咯并[1,2-A]嘧啶-6-羧酸 吡咯并[1,2-A]嘧啶-6-甲醛 叔丁基2-氨基-4-氯-5H-吡咯并[3,4-D]嘧啶-6(7H)-羧酸酯 叔丁基-4-氯-2-吗啉代-7H-吡咯并[2,3-D]嘧啶-7-甲酸甲酯 十二烷-1,12-二基二(苯甲基二甲基铵)二氯化 化合物PFE-360 亚乙基,2-氨基-1-(乙酯基<乙氧羰基>)-2-(甲酰基亚氨基)-,(2Z)-(9CI) 二环[2.2.1]庚-5-烯-2-羧酸,丁基酯,(1R,2R,4R)- [4-(1H-吡唑-4-基)-7H-吡咯并[2,3-D]嘧啶-7-基]甲基特戊酸酯 [3-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)环戊基]甲醇 [1-(乙基磺酰基)-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]氮杂环丁烷-3-基]乙腈磷酸盐 S-鲁索替尼